MedTrace Logo

A Research Study to Evaluate BLX-0871 in Healthy Adults

NCT07140081 · Status: NOT_YET_RECRUITING · Phase: PHASE1 · Type: INTERVENTIONAL · Enrollment: 76

Last updated 2025-08-24

No results posted yet for this study

Summary

This study will test an oral medicine called BLX-0871, which is being developed to improve metabolic health by activating AMP-activated protein kinase (AMPK), a key regulator of energy balance. The main goal is to see if BLX-0871 is safe and well tolerated when given to healthy adults. The study will also measure how the body processes BLX-0871, including how quickly it is absorbed, how long it stays in the blood, and how it is eliminated. Another objective is to see whether food affects the absorption of BLX-0871. It will also look at how the drug affects the body by looking at markers of AMPK activity.

Conditions

  • Normal Healthy Adults

Interventions

DRUG

BLX-0871

BLX-0871 Single or Multiple doses administered orally as a tablet

DRUG

Placebo

Participants will receive matching placebo of BLX-0871 for each of the oral cohorts.

Sponsors & Collaborators

  • Biolexis Therapeutics

    lead INDUSTRY

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
TRIPLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
65 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2025-09-30
Primary Completion
2026-04-30
Completion
2026-05-31

Countries

  • Australia

More Related Trials

Entities

Drugs

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT07140081 on ClinicalTrials.gov